🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccination schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccines during the pandemic and has focused upon alleged deaths following Covid vaccination in her brief position at the Food and Drug Administration.

Proposed Changes to Childhood Vaccine Program

Agency leaders were set to unveil radical changes to the childhood immunization program recently, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of alignment with much of the global community with no evidence for public health gain. This reveal has been delayed until the coming year.

Rather than Vinay Prasad, Dr. Høeg is listed to present at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth individual to head the center this year.

A Shift at the Regulatory Body

This interim role could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more in line with the Danish model, a country with comprehensive healthcare and a population roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Qualifications

Høeg has no obvious experience in drug development, approval processes or leadership, which has been typical for former leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who ran CBER have had.”

The drug center has an enormous portfolio at the agency, she stated.

“Everybody just pays attention on the new drug program, but the generic drug division approves a multitude of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one need to be looked after,” Woodcock said. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a substantial leadership component to the job, which supervises in excess of 5,000 personnel. “It is a huge administrative position, if you do it right,” Woodcock concluded.

Official Statement and Contentious Policies

In response to questions about Høeg’s fitness for the role and whether this assignment represents increased cooperation among agency officials on vaccines, a spokesperson said that the “questions rely on flawed presumptions”.

“Her resume is consistent with the functions of her role,” the representative said, citing the period Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a controversial expedited drug-approval program that apparently worried her former heads. “By what process are these drugs being chosen for this expedited pathway? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he remarked, “the FDA appears to be shifting towards less stringent regulations of most medications, aside from shots.”

Public Past Work on Immunizations

With vaccines, Dr. Høeg has a clearer, if concerning, history, some experts have noted. She authored a research paper using unverified public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have altered data to suggest Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership encompassed altering regulations for novel immunizations and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring young men from receiving Covid vaccines.

“She’s an thorough true believer who starts off with her beliefs and tailors the evidence to accommodate the evidence in a extremely disingenuous, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|